Differentiation of Human Induced Pluripotent Stem Cells into Erythroid Cells

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2020 Nov 17

PMID 33198819

Citations 19

Authors

Mohsen Ebrahimi

Mehdi Forouzesh

Setareh Raoufi

Mohammad Ramazii

Farhoodeh Ghaedrahmati

Maryam Farzaneh

Affiliations

Soon will be listed here.

Abstract

During the last years, several strategies have been made to obtain mature erythrocytes or red blood cells (RBC) from the bone marrow or umbilical cord blood (UCB). However, UCB-derived hematopoietic stem cells (HSC) are a limited source and in vitro large-scale expansion of RBC from HSC remains problematic. One promising alternative can be human pluripotent stem cells (PSCs) that provide an unlimited source of cells. Human PSCs, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), are self-renewing progenitors that can be differentiated to lineages of ectoderm, mesoderm, and endoderm. Several previous studies have revealed that human ESCs can differentiate into functional oxygen-carrying erythrocytes; however, the ex vivo expansion of human ESC-derived RBC is subjected to ethical concerns. Human iPSCs can be a suitable therapeutic choice for the in vitro/ex vivo manufacture of RBCs. Reprogramming of human somatic cells through the ectopic expression of the transcription factors (OCT4, SOX2, KLF4, c-MYC, LIN28, and NANOG) has provided a new avenue for disease modeling and regenerative medicine. Various techniques have been developed to generate enucleated RBCs from human iPSCs. The in vitro production of human iPSC-derived RBCs can be an alternative treatment option for patients with blood disorders. In this review, we focused on the generation of human iPSC-derived erythrocytes to present an overview of the current status and applications of this field.

Citing Articles

Conversion of placental hemogenic endothelial cells to hematopoietic stem and progenitor cells.

Liang G, Liu S, Zhou C, Liu M, Zhang Y, Ma D Cell Discov. 2025; 11(1):9.

PMID: 39875377 PMC: 11775181. DOI: 10.1038/s41421-024-00760-2.

Therapeutic delivery of oxygen using artificial oxygen carriers demonstrates the possibility of treating a wide range of diseases.

Mohanto N, Mondal H, Park Y, Jee J J Nanobiotechnology. 2025; 23(1):25.

PMID: 39827150 PMC: 11742488. DOI: 10.1186/s12951-024-03060-9.

In vitro erythropoiesis: the emerging potential of induced pluripotent stem cells (iPSCs).

Chukwuemeka C, Ndubueze C, Kolawole A, Joseph J, Oladipo I, Ofoezie E Blood Sci. 2024; 7(1):e00215.

PMID: 39726795 PMC: 11671056. DOI: 10.1097/BS9.0000000000000215.

Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights.

Razavi Z, Farokhi S, Mahmoudvand G, Karimi-Rouzbahani A, Farasati-Far B, Tahmasebi-Ghorabi S Front Cell Dev Biol. 2024; 12:1472103.

PMID: 39726717 PMC: 11669526. DOI: 10.3389/fcell.2024.1472103.

RNA modification in normal hematopoiesis and hematologic malignancies.

Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X MedComm (2020). 2024; 5(11):e787.

PMID: 39445003 PMC: 11496571. DOI: 10.1002/mco2.787.

References

Huang X, Wang Y, Yan W, Smith C, Ye Z, Wang J . Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation. Stem Cells. 2015; 33(5):1470-9. PMC: 4628786. DOI: 10.1002/stem.1969. View

Watts K, Adair J, Kiem H . Hematopoietic stem cell expansion and gene therapy. Cytotherapy. 2011; 13(10):1164-71. PMC: 3291512. DOI: 10.3109/14653249.2011.620748. View

Ingrungruanglert P, Amarinthnukrowh P, Rungsiwiwut R, Maneesri-le Grand S, Sosothikul D, Suphapeetiporn K . Wiskott-Aldrich syndrome iPS cells produce megakaryocytes with defects in cytoskeletal rearrangement and proplatelet formation. Thromb Haemost. 2014; 113(4):792-805. DOI: 10.1160/TH14-06-0503. View

Focosi D, Amabile G . Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside. Cells. 2017; 7(1). PMC: 5789275. DOI: 10.3390/cells7010002. View

Garcon L, Ge J, Manjunath S, Mills J, Apicella M, Parikh S . Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients. Blood. 2013; 122(6):912-21. PMC: 3739037. DOI: 10.1182/blood-2013-01-478321. View

Wu Y, Hu Z, Li Z, Pang J, Feng M, Hu X . In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs. Sci Rep. 2016; 6:18865. PMC: 4705535. DOI: 10.1038/srep18865. View

Volarevic V, Markovic B, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N . Ethical and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci. 2018; 15(1):36-45. PMC: 5765738. DOI: 10.7150/ijms.21666. View

Kotini A, Chang C, Chow A, Yuan H, Ho T, Wang T . Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017; 20(3):315-328.e7. PMC: 5337161. DOI: 10.1016/j.stem.2017.01.009. View

Shah S, Huang X, Cheng L . Concise review: stem cell-based approaches to red blood cell production for transfusion. Stem Cells Transl Med. 2013; 3(3):346-55. PMC: 3952923. DOI: 10.5966/sctm.2013-0054. View

10.

Zhou H, Rao M . Can cord blood banks transform into induced pluripotent stem cell banks?. Cytotherapy. 2015; 17(6):756-764. DOI: 10.1016/j.jcyt.2015.02.008. View

11.

Olgasi C, Talmon M, Merlin S, Cucci A, Richaud-Patin Y, Ranaldo G . Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A. Stem Cell Reports. 2018; 11(6):1391-1406. PMC: 6294075. DOI: 10.1016/j.stemcr.2018.10.012. View

12.

Prieto-Bermejo R, Romo-Gonzalez M, Perez-Fernandez A, Ijurko C, Hernandez-Hernandez A . Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side. J Exp Clin Cancer Res. 2018; 37(1):125. PMC: 6019308. DOI: 10.1186/s13046-018-0797-0. View

13.

Li P, Wu M, Lin Q, Wang S, Chen T, Jiang H . Key genes and integrated modules in hematopoietic differentiation of human embryonic stem cells: a comprehensive bioinformatic analysis. Stem Cell Res Ther. 2018; 9(1):301. PMC: 6225692. DOI: 10.1186/s13287-018-1050-7. View

14.

Horton P, Dumbali S, Wenzel P . Mechanoregulation in hematopoiesis and hematologic disorders. Curr Stem Cell Rep. 2020; 6(3):86-95. PMC: 7577202. DOI: 10.1007/s40778-020-00172-4. View

15.

Anstee D . Production of erythroid cells from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPS). Transfus Clin Biol. 2010; 17(3):104-9. DOI: 10.1016/j.tracli.2010.05.005. View

16.

Harding J, Mirochnitchenko O . Preclinical studies for induced pluripotent stem cell-based therapeutics. J Biol Chem. 2013; 289(8):4585-93. PMC: 3931020. DOI: 10.1074/jbc.R113.463737. View

17.

Kumar S, Geiger H . HSC Niche Biology and HSC Expansion Ex Vivo. Trends Mol Med. 2017; 23(9):799-819. PMC: 5600322. DOI: 10.1016/j.molmed.2017.07.003. View

18.

Xi J, Li Y, Wang R, Wang Y, Nan X, He L . In vitro large scale production of human mature red blood cells from hematopoietic stem cells by coculturing with human fetal liver stromal cells. Biomed Res Int. 2013; 2013:807863. PMC: 3581122. DOI: 10.1155/2013/807863. View

19.

Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee J, Tong L . Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014; 5:4372. PMC: 4107340. DOI: 10.1038/ncomms5372. View

20.

Menon T, Firth A, Scripture-Adams D, Galic Z, Qualls S, Gilmore W . Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell. 2015; 16(4):367-72. PMC: 4545662. DOI: 10.1016/j.stem.2015.02.005. View